<DOC>
	<DOCNO>NCT02031666</DOCNO>
	<brief_summary>The purpose study evaluate pharmacokinetics ( body medication ) relative bioavailability ( extent medication substance become available body ) JNJ-56021927 administer 7 test tablet formulation JNJ-56021927 compare softgel capsule formulation JNJ-56021927 healthy male participant fast condition single dose 240 mg .</brief_summary>
	<brief_title>A Study Assess Relative Bioavailability 7 Test Tablet Formulations JNJ-56021927 With Respect Capsule Formulation JNJ-56021927 Healthy Male Participants</brief_title>
	<detailed_description>This randomize ( study medication assign chance ) , open-label ( people know identity intervention ) , single-center , 8-treatment , parallel-group ( group participant treat time ) study . Approximately 120 participant ( 15 participant treatment group ) participate study . All participant randomly assign 1 8 possible treatment ( A , B , C , D , E , F , G , H ) . The study consist screen phase ( within 21 day first administration study medication ) , treatment phase 8 parallel single-dose treatment ( 8 day ) ; follow phase ( 42 day ) end-of-study early withdrawal assessment ( Day 57 ) . Safety evaluate assessment adverse event , clinical laboratory test , vital sign , physical examination monitor throughout study . The duration participation study individual participant approximately 78 day .</detailed_description>
	<criteria>During study 3 month receive study medication , must agree use adequate contraception method ( eg , vasectomy , doublebarrier , partner use effective contraception ) , always use condom sexual intercourse donate sperm Body mass index ( weight [ kg ] /height [ ] 2 ) 18 30 kg/m2 body weight less 50 kg Blood pressure ( participant supine 5 minute ) 90 140 mmHg systolic , inclusive , high 90 mmHg diastolic A 12lead electrocardiogram ( ECG ) consistent normal cardiac conduction function Nonsmoker 2 month prior study participation History current clinically significant medical illness include cardiac arrhythmia cardiac disease , hematologic disease , coagulation disorder , lipid abnormality , significant pulmonary disease ( include bronchospastic respiratory disease ) , diabetes mellitus , renal hepatic insufficiency , thyroid disease , neurologic psychiatric disease , infection Clinically significant abnormal value hematology , clinical chemistry urinalysis , physical examination , vital sign 12lead ECG screen admission study center deem appropriate investigator Presence sexual dysfunction ( eg , abnormal libido erectile dysfunction ) medical condition would affect sexual function Use prescription nonprescription medication ( include vitamin herbal supplement ) , except acetaminophen within 14 day first dose study drug schedule History clinically significant allergy know hypersensitivity vitamin E</criteria>
	<gender>Male</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>55 Years</maximum_age>
	<verification_date>October 2016</verification_date>
	<keyword>Healthy</keyword>
	<keyword>JNJ-56021927</keyword>
	<keyword>ARN-509</keyword>
	<keyword>Bioavailability</keyword>
</DOC>